

WAYS TO IMPROVE THE EFFECTIVENESS OF CHEMOTHERAPY PATIENTS WITH LARYNGEAL CANCER, WITH MALIGNANT TUMORS OF THE NOSE AND PARANASAL SINUSES

Ulmasov Firdavs Gayratovich

Samarkand State Medical University, Uzbekistan

Rakhimov Zhakhongir Khotamovich

Samarkand State Medical University, Uzbekistan

Nasretdinova Makhzuna Takhsinovna

Samarkand State Medical University, Uzbekistan

Abstract

At present, when planning complex treatment of patients with malignant tumors, an increasing role is given to chemotherapy. More than 50 antitumor chemotherapy drugs are used in clinical practice. This is due to the fact that neoplasms of different localization have different sensitivity to drugs. It was also found that they differ in their sensitivity to antitumor cytostatic agents in the same localization, prevalence, and histological structure. If the primary tumor focus in the head and neck area and metastases to regional lymph nodes, depending on the stage, can often be eliminated by radiation, surgical or combined treatment, then stable and long-term remission is ensured by the use of adjuvant chemotherapy.

Keywords complex treatment, complex treatment, underwent regional intra-arterial chemotherapy.

INTRODUCTION

Focusing in this paper on the possibilities of chemotherapy of the primary tumor focus as a component of complex treatment, it is necessary to emphasize that systemic polychemotherapy in some localities of malignant neoplasms of the head and neck is significantly inferior in effectiveness to

regional intra-arterial chemotherapy. The advantages of the latter turned out to be minimal general toxic manifestations with a simultaneous more maximal antitumor effect, which is also not the same for the same localization and histological structure of the neoplasm. In some patients, there

is a pronounced regression of the tumor up to its resorption, while in others the therapeutic effect is not significant or absent at all.

In order to increase the effectiveness of regional intra-arterial chemotherapy, we used a new method developed by us in the experiment to determine the individual sensitivity of the tumor and lymphoid tissue to chemopreparations, based on the registration of the electron pair spectrum of magnetic resonance (EPR) and the level of free radicals in experimental (with chemotherapy drugs) and control (damaged control by hyperthermia at a temperature of 60 °C) samples

After testing in experiments on laboratory animals, the method of adequate regional chemotherapy was tested and implemented in oncological practice. We treated two groups of patients (30 people each) with malignant tumors of the nose and near the sinuses. All of them, as a stage of complex treatment, underwent regional intra-arterial chemotherapy with determination (group 1) and without determination (group 2) of individual sensitivity of the neoplasm to chemotherapy drugs. The age of the subjects ranged from 16 to 70 years.

Of the 30 patients in group 1, 12 were men and 18 were women. Epithelial tumors were detected in 27 of them, non-epithelial in 3. The primary tumor size in 1 patient corresponded to T2, in 22 — to T3, and in 7 to T4. Regional lymph nodes were not palpated. Most often, neoplasms were sensitive to cyclophosphamide, thiotep, benzotep, 5-fluorouracil, methotrexate, and prospidine.

The use of adequate regional intra-arterial chemotherapy followed by radiation increased the survival rate to 5 years or more in 46.7% of patients. It should be noted that when the tumor regressed significantly, patients categorically refused to undergo surgery, or in inoperable cases, radiation was brought up to the full course dose. Transfacial rhinotomy was performed in 18 patients from this group at the final stage, of which a five-year follow-up period was observed in 12 (66.7%).

The individual sensitivity of the tumor to chemopreparations was not determined in group 2 patients, but the cytostatics to which the neoplasms in group 1 patients were most often sensitive were used during chemotherapy. In other words, the choice of chemopreparations, although it was made blindly empirically, but still their arsenal was very narrowed and concretized by previously conducted studies. There were 12 women and 18 men in this group. Epithelial tumors were also found in 27 patients, and non-epithelial tumors in 3 patients. Neoplasm corresponding to T2 was found in 4, T3 — in 17, T4 — in 9 people. Metastases to regional lymph nodes (N1) were detected in 1 patient with T3 and 1 more with T4. In regional intra-arterial chemotherapy, cyclophosphamide, THIOTEPH, and benzotep were used in the same doses and rhythm of administration. After regional intra-arterial chemotherapy followed by radiation, a 5-year period of swelling was observed in 33.3% of patients, and of the 17 people who underwent radical surgical intervention in the form of various rhinotomies at the final stage, this indicator was 52.9% at the same time, which is significantly lower than in the group of people with chronic rhinitis. preliminary adequate regional chemotherapy (66.7%).

Regional intra-arterial chemotherapy for cancer of the larynx, in addition to radiation exposure, was used in 87 men aged 37 to 77 years (83 with T3 and 4 with T4). In these patients, metastases to regional lymph nodes were absent.

Individual sensitivity of the neoplasm to cytostatic agents in this cohort of patients was assessed by recording intense blue fluorescence of tumor cells in biopsy tissue exposed to various chemopreparations. The optimal antitumor effect of the drug was judged by the maximum inhibition of luminescence.

The most effective drugs were sarcolysin, 5-fluorouracil, meta-trexate, thiotep, benzotep, cyclophosphane, etc.

In 44 (group 1) out of 87 individuals, regional intra-arterial chemotherapy was performed after

individual determination of the sensitivity of tumor tissue to chemotherapy drugs, and in 43 (Group 2) without it. Their drugs were selected by the "blind" method, but from the same "adequate" set as in patients of the 1st group. Of the 44 patients in group 1, the use of regional intra-arterial adequate chemotherapy followed by remote gamma therapy allowed achieving complete tumor regression in 25 (56.8%) patients. In group 2, as an adjunct to radiation therapy, it made it possible to preserve the larynx and all its functions only in 10 (32.5%) patients.

Analysis of failures in adequate regional intra-arterial chemotherapy with subsequent irradiation revealed a direct relationship between the effectiveness of treatment and the severity of vascularization of the pathological focus area. Intra-arterial administration of a ¹³¹I solution of albumin macroaggregate (131LMA) with subsequent scanning showed that with a more pronounced blood supply in the area of the tumor location, the effect of conservative treatment was much better than with weak and uneven vascularization of this area. In other words, with a better blood supply, more favorable conditions are created for the delivery of chemotherapy to the affected area and subsequent radiation exposure.

Thus, the work performed by us for more than 20 years once again convincingly demonstrates the undoubted value of individual selection of cytostatics after determining the sensitivity of a neoplasm to them. Combining and combining adequate antitumor chemopreparations of different classes seems to be more likely to have a pronounced therapeutic effect than prescribing empirically selected multicomponent schemes of systemic polychemotherapy, which may quite naturally include useless or even harmful drugs with a pronounced immunosuppressive effect at the same time. It is also clear that the sensitivity of a tumor to chemopreparations can certainly change during its development, so it should be considered justified to repeat a biopsy of the neoplasm for a control determination of its sensitivity to chemopreparations, especially in cases where the development of resistance is

noted. In recent years, there are more and more adherents to the use of adequate regional intra-arterial chemotherapy in cancer patients.

A. I. Gnatyshak and co-authors express doubts about the expediency of using cytostatics without taking into account the determination of individual sensitivity of the neoplasm to them. More categorically in this sense, A. M. Garin and co-authors believe that it is particularly important to overcome the natural and acquired resistance of tumor cells to cytostatic agents, as well as to determine the individual sensitivity of neoplasms to antitumor drugs, as a rational basis for improving the effectiveness of chemotherapy.

We do not in any way encourage an enthusiastic and illusory perception of the results we have obtained. We are deeply convinced that the widespread introduction into everyday practice of fast and automated methods for determining the individual sensitivity of tumors to cytostatic agents can make a significant contribution to the search for ways to improve the effectiveness of the treatment of cancer patients.

REFERENCES

1. Lund VJ, Howard D, Wei W. Tumours of the nose, sinuses and nasopharynx. Thieme 2014;1-595
2. Edge SB, Compton CC, Fritz AG, Greene FL, Trotti A. AJCC Cancer Staging Manual, 7th edn. New York: Springer, 2010
3. Dragonetti A, Gera R, Sciuto A, Scotti A, Bigoni A, Barbaro E et al. Sinonasal inverted papilloma: 84 patients treated by endoscopy and proposal for a new classification. *Rhinology* 2011;49:207-13
4. Nicolai P, Berlucchi M, Tomenzoli D, Cappiello J, Trimarchi M, Maroldi R et al. Endoscopic surgery for juvenile angiofibroma: when and how. *Laryngoscope* 2003;113:775-82
5. Ganly I, Patel SG, Singh B, Kraus DH, Bridger PG, Cantu G et al. Craniofacial resection for malignant paranasal sinus tumors: report of an

- international collaborative study. *Head Neck* 2005;27:575–84
6. Snyderman CH, Carrau RL, Kassam AB, Zano A, Prevedello D, Gardner P et al. Endoscopic skull base surgery: principles of endonasal oncological surgery. *J Surg Oncol* 2008;97:658–64
 7. Lund V, Stammberger H, Nicolai P, Castelnuovo P, Beal T, Beham A et al. European position paper on endoscopic management of the nose, paranasal sinuses and skull base. *Rhinol Suppl* 2010;22:1–144
 8. Lund V, Wei W. Endoscopic resection of malignant sinonasal tumors: an eighteen year experience. *Rhinology* 2015;40:407–11
 9. Nicolai P, Battaglia P, Bignami M, Bolzoni Villaret A, Delu G, Khrais T et al. Endoscopic surgery for malignant tumors of the sinonasal tract and adjacent skull base: a 10-year experience. *Am J Rhinol* 2008;22:308–16
 10. Eloy J, Vivero R, Hoang K, Civantos FJ, Weed DT, Morcos JJ et al. Comparison of transnasal endoscopic and open craniofacial resection for malignant tumors of the anterior skull base. *Laryngoscope* 2009;119:834–40
 11. Batra P, Luong A, Kanowitz SJ, Sade B, Lee J, Lanza DC et al. Outcomes of minimally invasive endoscopic resection of anterior skull base neoplasms. *Laryngoscope* 2010;120:9–16
 12. Devaiah AK, Andreoli MT. Treatment of esthesioneuroblastoma: a 16-year meta-analysis of 361 patients. *Laryngoscope* 2009;119:1412–16
 13. Rimmer J, Lund V, Beale T, Howard D, Wei W. Olfactory neuroblastoma – a 35 year experience and suggested follow-up protocol. *Laryngoscope* 2014;124:1542–49
 14. Lund VJ, Chisholm EJ, Howard DJ, Wei W. Sinonasal melanoma: a review of 115 cases assessing outcomes of surgery, postoperative radiotherapy and endoscopic resection. *Rhinology* 2012;50:203–10
 15. Zano A, Ferlito A, Rinaldo A, Gore M, Lund V, McKinney K et al. When, how and why to treat the neck in patients with esthesioneuroblastoma: a review. *Eur Arch Otolaryngol* 2010;267:1667–71
 16. Ang KK, Garden AS. *Radiotherapy for Head and Neck Cancer: Indications and Techniques*, 3rd edn. Lippincott, 2006
 17. Shakhanova Sh. Sh., Rakhimov M. N. Aspects of sarcopenia syndrome in oncological practice: diagnosis and treatment (literature review) // *Journal of Biomedicine and Practice*. 2023, vol. 8, issue 3, pp. 406-417
 18. Rakhimov M. N., Tulanov T. B., Shakhanova Sh. Sh., Aslanova M. L. Pathogenetic aspects of cancer anorexia // *Journal of Biomedicine and Practice*. 2023, vol. 8, issue 4, pp.192-201
 19. Dirix P, Vanstraelen B, Jorissen M, Vander Poorten V, Nuyts S. Intensity-modulated radiotherapy for sinonasal cancer: improved outcome compared to conventional radiotherapy. *Int J Radiat Oncol Biol Phys* 2010;78:998–1004
 20. Shakhanova Sh. Sh., Rakhimov N. M., & Murodov Sh. T.. (2024). Aspects of sarcopenia syndrome in oncological practice: diagnosis and treatment. *The American Journal of Medical Sciences and Pharmaceutical Research*, 6(02), 16–25. <https://doi.org/10.37547/TAJMSPR/Volume06Issue02-03>
 21. Bristol IJ, Ahamad A, Garden AS, Morrison WH, Hanna EY, Papadimitrakopoulou VA et al. Postoperative radiotherapy for maxillary sinus cancer: long term outcomes and toxicities of treatment. *Int J Radiat Oncol Biol Phys* 2007;68:719–30
 22. Brasnu D, Laccourreye O, Bassot V, Laccourreye L, Naudo P, Roux FX. Cisplatin-based neoadjuvant chemotherapy and combined resection for ethmoid sinus adenocarcinoma reaching and/or invading the skull base. *Arch Otolaryngol Head Neck Surg* 1996;122:765–68
 23. Dulguerov P, Allal AS. Nasal and paranasal

THE USA JOURNALS

THE AMERICAN JOURNAL OF MEDICAL SCIENCES AND PHARMACEUTICAL RESEARCH

(ISSN – 2689-1026)

VOLUME 06 ISSUE05

sinus carcinoma: how can we continue to make
progress? Curr Opin Otolaryngol Head Neck
Surg 2006;14:67-72